Early impact and performance characteristics of an established anal dysplasia screening program: program evaluation considerations.
BACKGROUND
Screening for invasive anal cancer and its precursors is being increasingly advocated as a response to increasing incidence among HIV-infected persons. We implemented a comprehensive screening program in 2001 and report our early experience to inform monitoring and evaluation of such programs. Our research aims were: (1) to estimate incidence of and mortality from invasive anal cancer (IAC) before (1995-2000) and after (2001-2005) screening program implementation and (2) to examine potential screening program quality indicators.


METHODS
The study cohort included all patients under care for HIV infection at UCSD Owen Clinic between 1995-2005. Person-time incidence rates (IR) and case survival of IAC were estimated for the pre-screening (1995-2000) and post-screening (2001-2005) periods. High resolution anoscopy (HRA) operator accuracy was estimated by kappa agreement between cyto-histologic comparisons. Program quality indicators included: (1) screening coverage; (2) percent technically unsatisfactory cytology smears; (3) time between 1st abnormal cytology and 1st HRA; and (4) time between last clinic visit and last cytology.


RESULTS
28 cases of IAC and 13,411 person-years were observed between 1995-2005. IRs (95% CI) pre-screening and post-screening were 199 and 216 per 100,000 person-years, respectively. There was no routine treatment of high grade squamous intraepithelial lesions (HSIL) during the study period. The percent of patients with IAC requiring chemoradiation decreased from 90.9% to 70.6% (p=0.36). There was a significant improvement in cyto-histologic agreement at HRA with increasing operator experience (r=0.92, p=0.025). Screening coverage was 73% of the target population. Among 14 providers, the percent unsatisfactory cytology smears averaged 27% but varied from 0 - 62%. The median time from 1st abnormal cytology to 1st HRA was 258 days. The median interval between the last cytology and the last clinic visit was 207 days.


CONCLUSIONS
(1) The overall IR of IAC did not decline in the screening era and was higher than previous estimates for HIV cohorts; (2) stage shift to IAC of more favorable prognosis is a reasonable screening goal; (3) HRA accuracy varied by provider experience; (4) because of delay in access to HRA, digital rectal exam should be combined with cytology screening to detect palpable disease.
Mathews
Christopher
C
Department of Medicine, University of California, San Diego, 200 West Arbor Drive. San Diego, CA 92103-8681, USA. cmathews@ucsd.edu
Caperna
Joseph
J
Cachay
Edward R
ER
Cosman
Bard
B
Acta Cytol. 2005 Jul-Aug;49(4):405-15
16124170
Fam Med. 1998 May;30(5):350-5
9597533
Prev Med. 2004 Aug;39(2):404-12
15226053
J Infect Dis. 2003 Jul 1;188(1):128-36
12825181
Oncologist. 2007 May;12(5):524-34
17522240
Sex Transm Infect. 2005 Oct;81(5):415-8
16199742
Obstet Gynecol. 1998 Oct;92(4 Pt 2):727-35
9764690
Fam Med. 2005 May;37(5):360-3
15883903
Clin Infect Dis. 2002 Nov 1;35(9):1127-34
12384848
Prev Med. 1977 Dec;6(4):487-99
600908
IARC Sci Publ. 1985;(66):45-63
4093187
Cytojournal. 2004 Oct 21;1(1):4
15504231
J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1610-5
15577418
N Engl J Med. 2007 Oct 18;357(16):1579-88
17942871
Ann Intern Med. 2002 Sep 3;137(5 Pt 2):435-78
12617574
Int J Gynecol Pathol. 1993 Apr;12(2):186-92
8463044
Diagn Cytopathol. 2005 Sep;33(3):152-6
16078257
Cochrane Database Syst Rev. 2004;(3):CD004323
15266529
Eur J Obstet Gynecol Reprod Biol. 2005 Aug 1;121(2):226-32
16054967
Eur J Cancer. 1998 Sep;34(10):1598-601
9893635
Am J Epidemiol. 2007 May 15;165(10):1143-53
17344204
Br J Surg. 2005 Sep;92(9):1133-6
16044425
BMJ. 1998 Aug 1;317(7154):307-12
9685274
Top HIV Med. 2003 Mar-Apr;11(2):45-9
12717041
Dis Colon Rectum. 2006 Jan;49(1):36-40
16283561
Colorectal Dis. 2003 May;5(3):206-13
12780879
Cancer. 2004 Jul 15;101(2):281-8
15241824
N Engl J Med. 2007 Oct 18;357(16):1589-97
17942872
Dis Colon Rectum. 2006 Oct;49(10):1648-9; author reply 1649-50
16972138
Sex Health. 2004;1(3):137-40
16335300
Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31
10219805
IARC Sci Publ. 1986;(76):185-98
3570404
Int J Colorectal Dis. 2002 Jul;17(4):203-15
12073068
Sex Transm Dis. 2007 Mar;34(3):170-3
16837830
J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5
16280701
Obstet Gynecol. 2003 Jan;101(1):29-37
12517642
J Natl Cancer Inst. 1999 Feb 3;91(3):252-8
10037103
Sex Transm Dis. 2005 May;32(5):314-20
15849533
Crit Rev Oncol Hematol. 2006 Mar;57(3):215-24
16371251
Dis Colon Rectum. 1997 Aug;40(8):919-28
9269808
Cancer. 2004 Sep 1;101(5 Suppl):1131-45
15316907
Am J Obstet Gynecol. 2001 Aug;185(2):507-13
11518918
Ned Tijdschr Geneeskd. 2000 Dec 2;144(49):2345-8
11129969
Br Med J (Clin Res Ed). 1986 Sep 13;293(6548):659-64
3092971
Am J Pediatr Hematol Oncol. 1992 May;14(2):117-28
1530116
Cancer Epidemiol Biomarkers Prev. 1994 Oct-Nov;3(7):619-26
7827594
Epidemiology. 2002 Nov;13(6):713-7
12410014
Clin Oncol (R Coll Radiol). 2004 Dec;16(8):530-5
15630846
J Med Screen. 2005;12(1):12-9
15825234
Am J Public Health. 1978 Feb;68(2):125-34
626255
J Gen Intern Med. 1990 Sep-Oct;5(5 Suppl):S14-6
2231057
J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5
15577408
Surg Today. 2006;36(10):885-91
16998682
Am J Epidemiol. 1988 Dec;128(6):1185-97
3057878
Br J Surg. 2006 May;93(5):531-8
16607677
Am J Obstet Gynecol. 2006 Mar;194(3):704-10
16522401
Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim
16396154
Health Qual Life Outcomes. 2007 Jan 08;5:3
17210071
Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85
15890590
Clin Infect Dis. 2006 Jul 15;43(2):223-33
16779751
Med J Aust. 1999 Mar 15;170(6):255-8
10212646
JAMA. 1999 May 19;281(19):1822-9
10340370
Gynecol Oncol. 2003 Jul;90(1):137-44
12821354
Surg Oncol. 2005 Nov;14(3):121-32
16165347
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9
9525431